PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 284 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer January 17, 2025 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 5 Ways Teens or Young Adults Can Cope With Loneliness During... July 11, 2023 El cáncer en mi comunidad: Ampliar el acceso a las pruebas... September 1, 2020 Load more HOT NEWS Good-bye, Old Friend After Losing His Mom To Breast Cancer, Man Founds ‘Not Just... COVID-19, Cancer, and Uncertainty: An Oncologist’s Perspective on Coping 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective
